Search results
FDA Approves Amgen’s BKEMV, the First Eculizumab Biosimilar | JD Supra
JD Supra· 17 hours agoOn May 28, 2024, the FDA approved Amgen’s BKEMV (eculizumab-aeeb), the first approved biosimilar of Alexion’s SOLIRIS (eculizumab). BKEMV was approved by the FDA as a 300 ...
Updates on Aflibercept Biosimilar Approvals and BPCIA Litigation | JD Supra
JD Supra· 17 hours agoRegeneron’s regulatory exclusivity for EYLEA expired on May 18, 2024. Two days later, on May 20, 2024, the FDA announced that it has approved Mylan Pharmaceuticals, Inc. and Biocon Biologics ...
Revolutionizing Biosimilar Management: How Amplify Rx Boosted Inova’s Operational Efficiency and...
Becker’s Hospital Review· 5 days agoThe growth and complexity of biosimilar agents for infusion therapy is generating a need for effective tools to optimize product selection and manage costs. Frequent changes ...
European Biosimilar Regulatory Update | JD Supra
JD Supra· 5 days agoIn the past few weeks, the European Commission provided marketing authorization for biosimilars of denosumab and omalizumab, as well as an ophthalmic formulation of bevacizumab ...
...s Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges ...
Benzinga· 3 days agoHumira, priced at nearly $7,000 per month, is the first high-selling drug to compete with numerous biosimilars. Following their launch last year, pharmacy benefit managers ...
Medicare Part D Plans Poorly Cover Adalimumab Biosimilars
Medscape· 5 days agoThis narrow coverage limits the cost-saving potential of these biosimilar competitors, expert said.
Denosumab Biosimilar Updates - June 2024 | JD Supra
JD Supra· 7 days agoOn May 21, Alvotech announced that it had entered into a license and supply agreement with Dr. Reddy’s Laboratories SA for the commercialization of AVT03, a proposed denosumab biosimilar ...
Ruconest and cost: Reducing long-term drug costs and more
Medical News Today· 6 days agoRuconest (C1 esterase inhibitor [recombinant]) is a brand-name biologic drug that’s prescribed for...
AbbVie's tight grip on Humira market raises concerns about biosimilars
Reuters via Yahoo News· 4 days agoAbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 6 days agoUzedy has shown up to 80% reduction in the risk of schizophrenia relapse versus placebo in a phase...
